CoChat
Sign Up
Cited by 126Nanoplatforms for cancer theranosticsMedical Imaging Techniques and ApplicationsPhotoacoustic and Ultrasonic Imaging

The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.

Multimodality imaging in nanomedicine and nanotheranostics

Open access
Li, Xue, Li, Xue, Zhang, Xue-Ning, Li, Xiao-Dong, Chang, Jin, Zhang, Xue-Ning, Li, Xiao-Dong, Chang, Jin·2016·Cancer Biology & Medicine
DOI 10.20892/j.issn.2095-3941.2016.0055PMC PMC5069837
Open this paper in CoChat — free account

Abstract

Accurate diagnosis of tumors needs much detailed information. However, available single imaging modality cannot provide complete or comprehensive data. Nanomedicine is the application of nanotechnology to medicine, and multimodality imaging based on nanoparticles has been receiving extensive attention. This new hybrid imaging technology could provide complementary information from different imaging modalities using only a single injection of contrast agent. In this review, we introduce recent developments in multifunctional nanoparticles and their biomedical applications to multimodal imaging and theragnosis as nanomedicine. Most of the reviewed studies are based on the intrinsic properties of nanoparticles and their application in clinical imaging technology. The imaging techniques include positron emission tomography, single-photon emission computed tomography, computerized tomography, magnetic resonance imaging, optical imaging, and ultrasound imaging.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.20892/j.issn.2095-3941.2016.0055

Cites

46 of 46 references verified0 citation errors · 0 not checkable

Statistics

Figures

1 (A) Decay-corrected whole-body coronal positron electron tomographic images of nude mice bearing human U87MG tumor at 1, 4, and 21 h after injection of 3.7 MBq of 64Cu-DOTA-IO, 64Cu-DOTA-IO-RGD, or 64Cu-DOTA-IO-RGD with 10 mg of c(RGDyK) peptide per kilogram (300 μg of iron-equivalent IO particles per mouse). (B) T2-weighted magnetic resonance images of nude mice bearing U87MG tumor before injection of IO nanoparticles (a, e) and at 4 h after tail-vein injection of DOTA-IO (b, f), DOTA-IO-RGD (c, g), and DOTA-IO-RGD with blocking dose of c(RGDyK) (d, h). Reproduced with permission from, Ref. 20. Copyright 2008 Society of Nuclear Medicine and Molecular Imaging. (C) Representative whole-body coronal positron electron tomographic images of U87MG tumor-bearing mice at 2, 6, 18, 24, and 48 h after intravenous (IV) injection of 100 μL (50 μg, 300 μCi) of 64CuCl 2, GSH-[ 64Cu]CIS/ZnS, and PEGylated GSH-[ 64Cu]CIS/ZnS RQDs (3 mice per group). (D) CRET images of U87MG tumor-bearing mice at 6 h after injection of 100 μL (300 μCi) of 64CuCl 2, GSH-[ 64Cu]CIS/ZnS, and PEGylated GSH-[ 64Cu]CIS/ZnS RQDs, respectively. Circle, tumor area (3 mice per group). These luminescence images were acquired without excitation light with open and red filter (>590 nm). Reproduced with permission from Ref. 21. Copyright 2014 American Chemical Society.
1 (A) Decay-corrected whole-body coronal positron electron tomographic images of nude mice bearing human U87MG tumor at 1, 4, and 21 h after injection of 3.7 MBq of 64Cu-DOTA-IO, 64Cu-DOTA-IO-RGD, or 64Cu-DOTA-IO-RGD with 10 mg of c(RGDyK) peptide per kilogram (300 μg of iron-equivalent IO particles per mouse). (B) T2-weighted magnetic resonance images of nude mice bearing U87MG tumor before injection of IO nanoparticles (a, e) and at 4 h after tail-vein injection of DOTA-IO (b, f), DOTA-IO-RGD (c, g), and DOTA-IO-RGD with blocking dose of c(RGDyK) (d, h). Reproduced with permission from, Ref. 20. Copyright 2008 Society of Nuclear Medicine and Molecular Imaging. (C) Representative whole-body coronal positron electron tomographic images of U87MG tumor-bearing mice at 2, 6, 18, 24, and 48 h after intravenous (IV) injection of 100 μL (50 μg, 300 μCi) of 64CuCl 2, GSH-[ 64Cu]CIS/ZnS, and PEGylated GSH-[ 64Cu]CIS/ZnS RQDs (3 mice per group). (D) CRET images of U87MG tumor-bearing mice at 6 h after injection of 100 μL (300 μCi) of 64CuCl 2, GSH-[ 64Cu]CIS/ZnS, and PEGylated GSH-[ 64Cu]CIS/ZnS RQDs, respectively. Circle, tumor area (3 mice per group). These luminescence images were acquired without excitation light with open and red filter (>590 nm). Reproduced with permission from Ref. 21. Copyright 2014 American Chemical Society.CC BY-NC-SA · PubMed Central
2 (A) SPECT/CT in vivo imaging in Wistar rats. Planar sequential scintigraphic images acquired during IV injection of 25 MBq of Gado- 6Si-NP_ 111In (a) and at 15 (b), 30 (c), and 60 min (d) after injection. Tomographic scintigraphy and X-ray CT of the whole body of the rat acquired at day 2, posterior projection (e1) and transversal slice (e2). LK: left kidney. RK: right kidney. B: bladder. UC: urine collector. (B) T1w.seq. Coronal images acquired before and at 3, 15, 30, and 60 min after IV injection of 50 μL of Gado-6Si-NP, centered on kidneys (a) and bladder (b). (C) Ventral (a1, 2, 3, and 4) and dorsal (b1, 2, 3, and 4) planar fluorescence reflectance images acquired at the end of IV injection of Gado- 6Si-NP (a1, b1), at 15 (a2, b2), 30 (a3, b3), and 60 min (a4, b4) after injection. Reproduced with permission from Ref. 24. Copyright 2011 American Chemical Society.
2 (A) SPECT/CT in vivo imaging in Wistar rats. Planar sequential scintigraphic images acquired during IV injection of 25 MBq of Gado- 6Si-NP_ 111In (a) and at 15 (b), 30 (c), and 60 min (d) after injection. Tomographic scintigraphy and X-ray CT of the whole body of the rat acquired at day 2, posterior projection (e1) and transversal slice (e2). LK: left kidney. RK: right kidney. B: bladder. UC: urine collector. (B) T1w.seq. Coronal images acquired before and at 3, 15, 30, and 60 min after IV injection of 50 μL of Gado-6Si-NP, centered on kidneys (a) and bladder (b). (C) Ventral (a1, 2, 3, and 4) and dorsal (b1, 2, 3, and 4) planar fluorescence reflectance images acquired at the end of IV injection of Gado- 6Si-NP (a1, b1), at 15 (a2, b2), 30 (a3, b3), and 60 min (a4, b4) after injection. Reproduced with permission from Ref. 24. Copyright 2011 American Chemical Society.CC BY-NC-SA · PubMed Central
3 (A) Three-dimensional maximum intensity projection images (anterior view) of a healthy New Zealand white rabbit (3 kg) obtained in CT (120 kV, 200 mA) and MR (3D FSPGR sequence, TR/TE=9.8/4.3) prior to and after IV administration (as indicated) of the liposome formulation of iohexol and gadoteridol. Reproduced with permission from Ref. 30. Copyright 2007 Springer. (B) In vivo PA images (a) and PA signal intensities (c) of the tumorous area recorded at 0, 2, 6, and 24 h after IV injection of Bi 2S 3 NPs into mice bearing 4 T1 tumors (dosage: 200 μL of Bi 2S 3 NPs solution containing 0.5 mg Bi). In vivo CT images (b) and signal intensities (d) of the tumorous area of another group of tumor-bearing mice recorded at 0, 2, 6, and 24 h after IV injection of Bi 2S 3 NPs (dosage: 200 μL of Bi 2S 3 NPs containing 1 mg Bi). The tumor site is pointed by red arrows. e: Infrared thermal images of tumor-bearing mice recorded during laser irradiation. f: H&E staining of tumor tissues harvested from the different groups of mice. Reproduced with permission from Ref. 33. Copyright 2016 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim.
3 (A) Three-dimensional maximum intensity projection images (anterior view) of a healthy New Zealand white rabbit (3 kg) obtained in CT (120 kV, 200 mA) and MR (3D FSPGR sequence, TR/TE=9.8/4.3) prior to and after IV administration (as indicated) of the liposome formulation of iohexol and gadoteridol. Reproduced with permission from Ref. 30. Copyright 2007 Springer. (B) In vivo PA images (a) and PA signal intensities (c) of the tumorous area recorded at 0, 2, 6, and 24 h after IV injection of Bi 2S 3 NPs into mice bearing 4 T1 tumors (dosage: 200 μL of Bi 2S 3 NPs solution containing 0.5 mg Bi). In vivo CT images (b) and signal intensities (d) of the tumorous area of another group of tumor-bearing mice recorded at 0, 2, 6, and 24 h after IV injection of Bi 2S 3 NPs (dosage: 200 μL of Bi 2S 3 NPs containing 1 mg Bi). The tumor site is pointed by red arrows. e: Infrared thermal images of tumor-bearing mice recorded during laser irradiation. f: H&E staining of tumor tissues harvested from the different groups of mice. Reproduced with permission from Ref. 33. Copyright 2016 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim.CC BY-NC-SA · PubMed Central
4 (A) In vivo T1 MR imaging and analysis of mice after intravenous injection of 4.8 nm GdIO@ZDS nanoparticles as contrast agents. a, b: MR images of mice after tail vein injection of 4.8 nm GdIO@ZDS nanoparticles (2.0 mg/kg) at 0, 10, 30, and 60 min, respectively. Blue arrows show the heart, red dot circles show the bladder, and the red dashed squares indicate the kidney. c: Quantification of signal changes (SNR ratio) in the heart, bladder, and kidney at different time points after administration ( n=3). Reproduced with permission from Ref. 41. Copyright 2013 American Chemical Society. (B) a-d: Four-modal imaging of the focused tumor from the tumor-bearing nude mouse 1 h after IV injection of NaLuF 4: Yb, Tm@NaGdF 4 ( 153Sm). a: In vivo UCL. b: X-ray CT. c: SPECT. d: MR images of the tumor. e: UCL confocal image of the paraffin section of tumor tissue. (f) Schematic illustration of tumor angiogenesis imaging using NaLuF 4:Yb,Tm@NaGdF 4 ( 153Sm) as the probe. Reproduced with permission from Ref. 44. Copyright 2013 American Chemical Society.
4 (A) In vivo T1 MR imaging and analysis of mice after intravenous injection of 4.8 nm GdIO@ZDS nanoparticles as contrast agents. a, b: MR images of mice after tail vein injection of 4.8 nm GdIO@ZDS nanoparticles (2.0 mg/kg) at 0, 10, 30, and 60 min, respectively. Blue arrows show the heart, red dot circles show the bladder, and the red dashed squares indicate the kidney. c: Quantification of signal changes (SNR ratio) in the heart, bladder, and kidney at different time points after administration ( n=3). Reproduced with permission from Ref. 41. Copyright 2013 American Chemical Society. (B) a-d: Four-modal imaging of the focused tumor from the tumor-bearing nude mouse 1 h after IV injection of NaLuF 4: Yb, Tm@NaGdF 4 ( 153Sm). a: In vivo UCL. b: X-ray CT. c: SPECT. d: MR images of the tumor. e: UCL confocal image of the paraffin section of tumor tissue. (f) Schematic illustration of tumor angiogenesis imaging using NaLuF 4:Yb,Tm@NaGdF 4 ( 153Sm) as the probe. Reproduced with permission from Ref. 44. Copyright 2013 American Chemical Society.CC BY-NC-SA · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 46 references

Research works printed but not linked: 1

  1. [53]Niu C Wang Z Lu G Krupka TM Sun Y You Y Gold–nanoshelled microcapsules: a theranostic agent for ultrasound contrast imaging and photothermal therapy Angew Chem Int Ed Engl 2011 50 3017 21 21404389

Cited by

Sorted by citations

Related

See all

Metadata

Authors
Li, X., Li, X., Zhang, X.-N., Li, X.-D., Chang, J., Zhang, X.-N., Li, X.-D., & Chang, J.
Venue
Cancer Biology & Medicine
Publisher
China Anti-cancer Association
Published
2016
Volume
13
Issue
3
Pages
339-348
ISSN
2095-3941 (ISSN-L)
DOI
10.20892/j.issn.2095-3941.2016.0055
PMC
PMC5069837
OpenAlex
W2527625794
Cited by
126
References
46
Citations by year
2026: 5 · 2025: 16 · 2024: 12 · 2023: 13 · 2022: 13 · 2021: 19 · 2020: 20 · 2019: 12 · 2018: 8 · 2017: 8
FWCI
4.50
Type
journal article
Language
en
Open access
Licence
cc-by
Locations
  • Cancer Biology and Medicine (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by-nc-sa)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Topics
  • Physical Sciences › Engineering › Biomedical Engineering › Nanoplatforms for cancer theranostics
  • Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Medical Imaging Techniques and Applications
  • Physical Sciences › Engineering › Biomedical Engineering › Photoacoustic and Ultrasonic Imaging
Keywords
multimodal imaging, nanomedicine, theranostics, multifunctional nanoparticles, tumor diagnosis, hybrid imaging, positron emission tomography, single photon emission computed tomography, magnetic resonance imaging, optical imaging, ultrasonography, contrast media

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review